Vesigen to Present New Preclinical Data on Engineered ARMMs Technology at 2024 ASGCT Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #ASGCT2024--Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, today announced that the Company will be presenting 10 posters sharing new preclinical data from its engineered ARMMs platform at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. The conference will be held from May 7-11 in Baltimore, Maryland. Vesigen’s delivery technology has